관련문헌 등
·Current Medical Diagnosis & Treatment, 2019
·ERCP, 3e, 2019
·Clinical practice guideline for post-ERCP pancreatitis. Japanese Society of Gastroenterology(2017) J Gastroenterol DOI:10.1007/s00535-017-1359-5
·Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline ？ Updated June 2014
·ASGE(American Society For Gastrointestinal Endoscopy), Adverse events associated with ERCP(2017)
·총담관결석의 진료 가이드라인, 대한췌담도학회(2013)
·American College of Gastroenterology Guideline: Management of Acute Pancreatitis. Am J Gastroenterol 2013;108(9):1400-15.
·Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015, Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci;2015;22:405-432
·급성 췌장염 진료 권고안: 급성 췌장염의 초기 치료, 대한췌담도학회(2013)
·Consensus guidelines on severe acute pancreatitis, The Italian Association for the Study of the Pancreas (AISP), Digestive and Liver Disease;2015;47:532？543
·Tadashi Takeuchi et al. Clinical Evaluation of FUT-175(Nafamostat mesilate) on Pancreatitis, A Double-Blind Controlled Study with Gabexate Mesilate. Digestive Medicine 1984;1:269
·Ge Yu et al. Nafamostat Mesilate for Prevention of Post-ERCP Pancreatitis. Pancreas 2015;44:561？569.
·Kubiliun et al. Evaluation of Pharmacologic Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Systematic Review. Clinical Gastroenterology and Hepatology 2015;13:1231？1239
·Yuhara et al. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol. 2014;49(3):388-99.
·Ohuchida et al. Randomized Controlled Trial for Efficacy of Nafamostat Mesilate in Preventing Post？Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Pancreas 2015;44:415-421.
·Park et al. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: A prospective, randomized trial. Pancreatology;2014;14:263-267
·Critical Care Nephrology, 3e. 2019
·Brenner and Rector's The Kidney, 10e. 2016
·Textbook of Critical Care, 7e. 2017
·Handbook of Dialysis Therapy, 5e. 2017
·The Japanese Clinical Practice Guideline for acute kidney injury 2016, Journal of Intensive Care 2018;6:48
·Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. 2012. Therapeutic Apheresis and Dialysis 2012;16(5):387？435
·KDIGO Clinical Practice Guideline for Acute Kidney Injury, 2012.
·Eun Yi Kim et al. Low-Dose Nafamostat Mesilate in Hemodialysis Patients at High Bleeding Risk. The Korean Journal of Nephrology 2011;30:61-66
·T. Akizawa et al. Clinical Benefits of Nafamostat Mesilate as an Anticoagulant for High bleeding Risk Hemodialysis. Artificial Organs 1991;14:209-212
·Hyun Chul Kim et al. A Multi-Center Phase Ⅲ Clinical Trial to Assess the Influence to Bleeding and Anticoagulant Effect of Nafamostat Mesilate(Futhan) in Hemodialysis Patients with High Bleeding-Risk. The Korean Journal of Nephrology 2004;23(6):920-926.
·Yang et al. Superior Outcome of Nafamostat Mesilate as an Anticoagulant in Patients Undergoing Maintenance Hemodialysis with Intracerebral Hemorrhage. Renal Failure 2009;31:668-675
·T. Akizawa et al. Nafamostat Mesilate: A Regional Anticoagulant for Hemodialysis in Patients at High Risk for Bleeding. Nephron 1993;64:376-381
·Matsuo et al. Anticoagulation with Nafamostat Mesilate, a Synthetic Protease Inhibitor, in Hemodialysis Patients with a Bleeding Risk. Haemostasis 1993;23:135-141.
·Critical Heart Disease in Infants and Children. 3e.
·Oh’s Intensive Care Manual. 8e.
·Extracorporeal Life Support Organization(ELSO): General Guidelines for all ECLS Cases. August, 2017.
·Lim JY, et al. Anticoagultaion During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin. Ann Thorac Surg.2016 Aug;102(2):534-9.
·Park JH, et al. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs 2015; 38(11): 595 ？ 9.
·Han SJ, et al. Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation. J Korean Med Sci 2011;26: 945-950.